Drugs / Cagrilintide
Cagrilintide
Trials 44 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 122 trials | ||||||
| Phase 1 | NCT07607587 | May 2026 → Nov 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07605052 | May → Sep 2026 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07557953 | Apr 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07527195 | Apr 2026 → Apr 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07411560 | Feb 2026 → Jan 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07010432 | Jun 2025 → May 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06719011 | Dec 2024 → Mar 2026 overdue | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06716307 | Dec 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06403761 | May 2024 → Dec 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06289504 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06207877 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06267092 | Feb 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05804162 | Apr → Aug 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05564104 | Apr 2023 → Sep 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05254158 | Mar → Sep 2022 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04940078 | Jul 2021 → Jan 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04209049 | Jan 2020 → Jan 2021 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04074174 | Sep 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03787225 | Jan → Jun 2019 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03600480 | Jul 2018 → Jun 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02958085 | Nov 2016 → Jan 2018 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02300844 | Dec 2014 → Mar 2016 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07357740 | Aug 2026 → Aug 2027 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 2 | NCT06409130 | May 2024 → Nov 2025 | alcoholic liver disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06131372 | Apr 2024 → Sep 2025 | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05016882 | Aug 2021 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT04982575 | Aug 2021 → Jul 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03856047 | Mar 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT07357766 | Jun 2026 → Nov 2027 | obesity disorder | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT07564414 | May 2026 → Feb 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07253285 | Jan 2026 → Mar 2030 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07220759 | Nov 2025 → May 2027 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07220642 | Nov 2025 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06780449 | Feb 2025 → Aug 2028 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06534411 | Nov 2024 → Jun 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06388187 | Jun 2024 → Apr 2026 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06221969 | Jan 2024 → Mar 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06131437 | Nov 2023 → Dec 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06065540 | Sep 2023 → Nov 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05996848 | Aug 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05813925 | Apr 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05669755 | Mar 2023 → Sep 2027 expected | cardiovascular disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05394519 | Feb 2023 → Jan 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05567796 | Nov 2022 → Oct 2024 overdue | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06323161 Comparator | Mar 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06323174 Comparator | Mar 2024 → Oct 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 48 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cagrilintide | “Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor...” PMID 42228334 ↗ Jun 202637“Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.” NCT07357766 ↗ “Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.” NCT07357740 ↗ “Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.” NCT07564414 ↗ |
| Known as | cagrilintide B | “Participants will receive a single subcutaneous (s.c.) dose of CagriSema (cagrilintide B and semaglutide I) in DV3384 pen-injector in period 1 followed by a single s.c. dose of...” NCT06716307 ↗ |
| Known as | Cagrilintide component of cagrisema | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802169 ↗ |
| Known as | NNC0174 0833 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05254158 ↗ |
| Action | Activate | “Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management” PMID 42228334 ↗ Jun 2026 |
| Modality | Peptide | “Cagrilintide, a long-acting amylin analogue” PMID 33894838 ↗ Apr 2021 |
| Modality | Protein / enzyme biologic | — CHEMBL4802169 ↗ |
| Route | Subcutaneous | “single s.c. (subcutaneous/under the skin) dose” NCT02300844 ↗ |